The nature of infectious contacts and the relative importance of contact, large-droplet spray, and aerosol (droplet nuclei) transmission remain controversial ([@r1][@r2][@r3][@r4][@r5]--[@r6]). Nonpharmaceutical interventions have been employed to control and reduce the impact of influenza epidemics and pandemics ([@r7]). However, to design effective nonpharmaceutical interventions, it is necessary to accurately define the relative and absolute contribution of each route of transmission ([@r8]) and implement interventions that impede those of principal importance.

Mathematical models that have been used to understand and estimate the contribution of each mode are very sensitive to estimates of unmeasured parameters ([@r9], [@r10]), such as the viral load in exhaled breath and coughs and the frequency of sneezing by influenza cases ([@r8]). However, due to limitations inherent to sampling virus shedding via various routes from infected individuals, and the difficulty of distinguishing routes of transmission in observational studies, the quantitative dynamics and relative contributions of each route remain elusive ([@r4], [@r8]). Recent reports have shown that infectious influenza virus can be recovered from exhaled aerosols ([@r11][@r12]--[@r13]). These studies, based on small numbers of cases or artificial breathing maneuvers, do not provide sufficient data to quantify the extent of aerosol shedding during natural breathing, nor do they identify the contributions of spontaneous coughs and sneezes commonly thought to be the most important mechanism for viral shedding, or identify other factors that may impact viral aerosol shedding. We address these key knowledge gaps by characterizing influenza virus in exhaled breath from community-acquired influenza cases during natural breathing, prompted speech, coughing, and sneezing, and assess the infectivity of naturally occurring influenza aerosols.

Results {#s1}
=======

We screened 355 volunteers with acute respiratory illness; the 178 volunteers who met enrollment criteria provided 278 visits for sample collection. We confirmed influenza infection in 156 (88%) of the enrolled participants using qRT-PCR; 152 had at least one positive nasopharyngeal (NP) swab and 4 (3%) were confirmed based on positive aerosol samples alone. NP swab analysis was positive for 8 (33%) of 24 randomly selected volunteers from among the 177 screened who did not meet enrollment criteria; thus, sensitivity and specificity of our enrollment criteria, during the 2012--2013 season, were ∼73% \[95% confidence interval (CI) 62--84%\] and 84% (95% CI 80--88%), respectively. In the reported analyses, we excluded 8 visits made on the day of symptom onset, 10 made \>3 d after onset, 7 with missing data for cough, and 3 with incomplete qRT-PCR data ([Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental) and [Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)). The resulting dataset for confirmed cases with complete data on RNA copies, cough, and symptoms included 218 visits by 142 cases: 89 influenza A (83 H3, 3 pdmH1, 3 unsubtypable), 50 influenza B, and 3 dual influenza infection cases.

Our study population ([Table 1](#t01){ref-type="table"}) consisted mostly of young adults (19--21 y) with a high asthma prevalence (21%), normal body mass index (BMI, median = 22.7; 7% underweight, 20% overweight, and 8% obese) ([Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)), and a low self-reported influenza vaccination rate (22%). We observed at least one cough during 195 (89%) and one or more sneezes during 11 (5%) of the 218 visits. Cough frequency varied considerably, from 5 per 30 min at the 25th percentile to 39 per 30 min at the 75th. Most volunteers rated their upper respiratory symptoms as mild to moderate, systemic symptoms as moderate to severe, and lower respiratory symptoms as mild ([Fig. 1](#fig01){ref-type="fig"}).

###### 

Characteristics of study population

  Variable                                                                   Screened only       Enrolled            Complete data
  -------------------------------------------------------------------------- ------------------- ------------------- -------------------
  No. of participants                                                        177                 178                 142
  Breath collection visits                                                   0                   278                 218
  Male (%)                                                                   89 (50)             91 (51)             69 (49)
  Influenza vaccination current season (%)                                   53 (30)             42 (24)             31 (22)
  Influenza vaccination previous season (%)                                  77 (44)             63 (35)             48 (34)
  Influenza vaccination current & previous (%)                               39 (22)             32 (18)             22 (15)
  Asthma, self-reported (%)                                                  --                  38 (21)             30 (21)
  Smoker, current (%)                                                        --                  30 (17)             21 (15)
  Antiviral medication last 24 h (%)                                         2                   11 (6)              7 (5)
  Age, y (IQR)                                                               20 (19--22)         21 (19--22)         20 (19--21)
  BMI (IQR)                                                                  23.6 (21.3--26.2)   23.2 (21.0--25.7)   22.7 (20.9--25.5)
  Body temperature measured (IQR)                                            36.9 (36.8--37.1)   37.2 (36.9--37.7)   37.2 (36.9--37.6)
  Median coughs/30 min (IQR)[\*](#tfn1){ref-type="table-fn"}                 --                  17 (6--39)          18 (5--39)
  Median sneezes/30 min (IQR)                                                --                  0 (0-0)             0 (0--0)
  Median upper respiratory symptoms (IQR)[^†^](#tfn2){ref-type="table-fn"}   7 (4--9)            6 (5--8)            7 (5--8)
  Median lower respiratory symptoms (IQR)                                    2 (1--4)            3 (2--5)            3 (2--6)
  Median systemic symptoms (IQR)                                             6 (3--9)            8 (5--11)           8 (5--11)

IQR = interquartile range.

Cough, sneeze, and symptom scores are reported per visit.

Twelve symptoms were rated from 0 to 3 with maximum possible composite score of 15 for upper respiratory, 9 for lower respiratory, and 15 for systemic symptoms.

![Histograms of symptom scores. (*A*) Upper respiratory symptoms (runny nose, stuffy nose, sneezing, sore throat, and earache, score range 0--15). (*B*) Lower respiratory symptoms (chest tightness, shortness of breath, and cough, score range 0--9). (*C*) Systemic symptoms (malaise, headache, muscle/joint ache, fever/sweats/chills, and swollen lymph nodes, score range 0--15).](pnas.1716561115fig01){#fig01}

Infectious virus was recovered from 52 (39%) fine-aerosol samples and 150 (89%) NP swabs ([Table 2](#t02){ref-type="table"}). Quantitative cultures were positive for 30% of the fine-aerosol samples, with a geometric mean (GM) for positive samples of 37 fluorescent focus units (FFU) per 30-min sample ([Fig. 2*A*](#fig02){ref-type="fig"}) and for 62% of NP swabs with GM for positive samples of 2,500. Using Tobit analysis to adjust the estimate of the GM for the presence of samples below the limit of detection, we obtained a GM 1.6 (95% CI 0.7--3.5) for fine aerosols and a GM 60.6 (95% CI 22.7--1.6 × 10^2^) for NP swabs.

###### 

Viral shedding

  Variable                     NP swab              Coarse aerosol      Fine aerosol
  ---------------------------- -------------------- ------------------- -------------------
  Culture passage                                                       
   Valid assays                169                  NA                  134
   Positive (%)                150 (89)             NA                  52 (39)
  Quantitative culture (FFU)                                            
   Valid assays                159                  NA                  136
   Positive (%)                98 (62)              NA                  41 (30)
   GM (GSD)                    2.5 × 10^3^ (23)     NA                  37 (4.4)
   Range                       ND -- 5.1 × 10^5^    NA                  ND -- 1.1 × 10^3^
  RNA copies                                                            
   Valid assays                218                  218                 218
   Positive (%)                211 (97)             88 (40)             166 (76)
   GM (GSD)                    8.2 × 10^8^ (52)     1.2 × 10^4^ (14)    3.8 × 10^4^ (13)
   Range                       ND -- 3.8 × 10^11^   ND -- 4.3 × 10^8^   ND -- 4.4 × 10^7^

GSD, geometric SD (only positive samples were included in computation of GM and GSD); NA, not assayed; ND, not detected.

![Viral shedding: (*A*) infectious influenza virus (fluorescent focus counts) in NP swabs and fine aerosols and (*B*) RNA copies in NP swabs, coarse, and fine aerosols. (*C* and *D*) Scatter plots and Spearman correlation coefficients of infectious virus plotted against RNA copies for (*C*) NP swabs and for (*D*) fine-aerosol samples. (*E*) The effect of day after symptom onset on RNA copies observed in NP swabs, coarse, and fine aerosols plotted as GM adjusted for missing data using Tobit analysis with error bars denoting 95% CIs. (*F--H*) The effect of cough frequency on RNA copies observed in (*F*) NP swabs, (*G*) coarse aerosols, and (*H*) in fine aerosols. Coarse: aerosol droplets \>5 µm; Fine: aerosol droplets ≤5 µm in aerodynamic diameter.](pnas.1716561115fig02){#fig02}

Influenza virus RNA was detected in 76% of the fine-aerosol samples, 40% of the coarse-aerosol samples, and 97% of the NP swabs of enrolled volunteers. For the positive samples, the GM viral RNA content of fine-aerosol samples was 3.8 × 10^4^, for coarse aerosols was 1.2 × 10^4^, and for NP swabs was 8.2 × 10^8^ ([Fig. 2*B*](#fig02){ref-type="fig"}). The adjusted GMs were 1.2 × 10^4^ (95% CI 7.0 × 10^3^ to 1.9 × 10^4^) for fine aerosols and 6.0 × 10^2^ (95% CI 3.0 × 10^2^ to 1.2 × 10^3^) for coarse aerosols. Quantitative culture was correlated with RNA copies in both NP swabs ([Fig. 2*C*](#fig02){ref-type="fig"}) (*r* = 0.58) and fine aerosols ([Fig. 2*D*](#fig02){ref-type="fig"}) (*r* = 0.34). The time course of shedding is shown in [Fig. 2*E*](#fig02){ref-type="fig"}.

Viral RNA in NP swabs was not correlated with cough frequency (number of coughs per 30 min) ([Fig. 2*F*](#fig02){ref-type="fig"} and [Fig. S2*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)) (*r* = 0.02). Viral RNA in coarse aerosols was weakly correlated with cough frequency ([Fig. 2*G*](#fig02){ref-type="fig"} and [Fig. S2*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)) (*r* = 0.24). However, viral RNA copy number in fine aerosols was moderately well correlated with cough frequency ([Fig. 2*H*](#fig02){ref-type="fig"} and [Fig. S2*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)) (*r* = 0.45). Only 3 (13%) of 23 coarse-aerosol samples where no coughs were observed had detectable viral RNA, while 11 (48%) of the corresponding 23 fine-aerosol samples had detectable viral RNA and 8 were positive by culture. RNA copies in the fine-aerosol, no-cough samples ranged up to 3.7 × 10^5^ (adjusted GM 1.5 × 10^3^, 95% CI 4.2 × 10^2^ to 5.3 × 10^3^) and infectious virus to 1.4 × 10^2^ FFU per 30-min sample. The few sneezes observed were not associated with greater RNA copy numbers in either coarse or fine aerosols ([Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)).

Results of regression analyses to identify predictors of viral RNA shedding are shown in [Table 3](#t03){ref-type="table"}, controlled for random effects of subject and repeated observations on individuals.

###### 

Predictors of viral RNA shedding

  Parameter                                                     NP swab                      Coarse aerosol                Fine aerosol                                                                          
  ------------------------------------------------------------- ---------------------------- ----------------------------- -------------------------- -------------------------- ------------------------------- -----------------------------
  Age                                                           **0.85\*\* (0.72--1.0)**     **0.78\*\*\* (0.66--0.92)**   1.0 (0.90--1.2)            1.0 (0.90--1.1)            0.99 (0.88--1.1)                1.0 (0.90--1.1)
  Male                                                          0.34 (0.14--2.5)             0.68 (0.17--2.8)              1.7 (0.52--5.6)            1.7 (0.54--5.5)            **2.4\* (0.88--6.5)**           1.3 (0.39--4.2)
  Asthma                                                        3.8 (0.63--22.9)             ---                           1.38 (0.32--6.04)          ---                        2.6 (0.77--8.95)                ---
  Smoker                                                        2.3 (0.30--18.2)             ---                           0.48 (0.09--2.7)           ---                        1.5 (0.36--6.1)                 ---
  BMI                                                           1.3 (0.58--2.7)              ---                           **1.9\* (0.92--3.98)**     1.8 (0.83--3.8)            **1.7\* (0.98--2.9)**           **2.5\*\*\* (1.4--4.3)**
  Vaccination[^†^](#tfn3){ref-type="table-fn"} (current year)   1.3 (0.22--7.6)              ---                           1.4 (0.34--5.9)            ---                        **2.8\* (0.85--9.3)**           ---
  Vaccination (previous year)                                   1.55 (0.45--5.5)             ---                           0.71 (0.15--3.3)           ---                        2.3 (0.79--6.6)                 ---
  Vaccination (current and previous)                            0.77 (0.10--5.7)             ---                           1.13 (0.22--5.7)           ---                        **2.1\*\*\* (1.3--3.2)**        **6.3\*\*\* (1.9--21.5)**
  Antiviral medication                                          1.1 (0.03--33.9)             ---                           0.64 (0.04--11.5)          ---                        1.04 (0.09--12.0)               ---
  Influenza A                                                   0.67 (0.13--3.3)             ---                           1.0 (0.18--5.5)            ---                        0.44 (0.13--1.5)                ---
  Log (NP swab)                                                 ---                          ---                           1.3 (0.91--1.82)           ---                        1.2 (0.76--1.78)                ---
  Day 2 postonset                                               2.13 (0.48--9.5)             ---                           **0.34\* (0.10--1.02)**    **0.34\* (0.10--1.1)**     **0.44\* (0.18--1.05)**         **0.47**\* **(0.20--1.1)**
  Day 3 postonset                                               0.55 (0.11--2.8)             ---                           **0.29\* (0.08--1.03)**    0.30 (0.08--1.03)          **0.20\*\*\*\* (0.08--0.52)**   **0.24\*\*\* (0.09--0.59)**
  Fever[^‡^](#tfn4){ref-type="table-fn"}                        3.6 (0.76--17.2)             ---                           0.70 (0.19--2.7)           ---                        1.7 (0.64--4.5)                 ---
  No. of coughs                                                 1.3 (0.65--2.8)              ---                           **2.1\*\*\* (1.2--3.8)**   **2.3\*\*\* (1.3--4.0)**   **2.9\*\*\*\*\* (1.9--4.6)**    **2.6\*\*\*\* (1.6--4.2)**
  Upper respiratory symptoms                                    **3.4\*\*\*\* (1.8--6.6)**   **2.9\*\*\* (1.5--5.7)**      0.76 (0.44--1.3)           ---                        0.88 (0.58--1.4)                ---
  Lower respiratory symptoms                                    **3.2\* (0.96--10.8)**       1.2 (0.32--4.8)               0.94 (0.36--2.5)           ---                        1.9 (0.86--4.1)                 ---
  Systemic symptoms                                             **5.3\*\*\* (1.6--17.7)**    2.4 (0.31--18.3)              0.86 (0.33--2.3)           ---                        1.8 (0.82--3.7)                 ---
  Male × no. of coughs                                          ---                          ---                           ---                        ---                        ---                             **3.2\*\* (1.1--9.3)**

Effect estimates are shown as the ratio of male to female, day 2 or day 3 to day 1, type A to B, yes to no vaccination, or fold-increase for an IQR change in age, the number of coughs, symptom reports, or BMI, or ratio of male to female coughs over the IQR (95% confidence interval for the effect estimate). All analyses are controlled for random effects of subject and sample within subject and for censoring by limit of detection using Tobit regression. \**P* \< 0.10, \*\**P* \< 0.05, \*\*\**P* \< 0.01, **\*\*\*\****P* \< 0.001, **\*\*\*\*\****P* \< 0.0001 from Tobit regression models with random effect of subject and sample within subject. Adjusted models were selected using the Akaike information criterion from initial models, with all unadjusted parameters having *P* \< 0.10, shown in bold.

Vaccination = self-reported influenza vaccination.

Fever = T ≥ 37.8 measured at visit.

The day after symptom onset (comparing day 1 postonset with days 2 and 3) was associated with a significant decline in viral RNA shed into fine aerosols (*P* \< 0.05 for day 2 and *P* \< 0.01 for day 3 in adjusted models), a borderline significant decline in coarse-aerosol shedding (*P* \< 0.10), and was not associated with a significant change in shedding detected in NP swabs (*P* \> 0.10).

In regression analyses, cough frequency was significantly associated with increased fine- (*P* \< 0.001 to \<0.0001) and coarse- (*P* \< 0.01) aerosol shedding, but was not associated with NP shedding. Fine-aerosol shedding was significantly greater for males. Analysis of an interaction of cough with sex indicated that males produced, on average, 3.2 times more virus than did females per cough. However, females also coughed significantly (*P* = 0.005) more frequently than males: 33 (SD 39) per 30-min observation and 21 (SD 21), respectively ([Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)).

BMI was positively associated with shedding in fine and coarse aerosols in unadjusted models (*P* \< 0.10). BMI was retained in the best-fitting adjusted models for both fine and coarse aerosols, where it was significantly associated with fine-aerosol shedding (*P* \< 0.05). However, BMI was not associated with shedding detected in NP swabs (*P* \> 0.10). Standard categories of BMI were not as good a fit as the continuous BMI and were not significantly associated with shedding ([Table S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)), although a positive trend is evident for overweight and obese individuals in the adjusted model.

Self-reported vaccination for the current season was associated with a trend (*P* \< 0.10) toward higher viral shedding in fine-aerosol samples; vaccination with both the current and previous year's seasonal vaccines, however, was significantly associated with greater fine-aerosol shedding in unadjusted and adjusted models (*P* \< 0.01). In adjusted models, we observed 6.3 (95% CI 1.9--21.5) times more aerosol shedding among cases with vaccination in the current and previous season compared with having no vaccination in those two seasons. Vaccination was not associated with coarse-aerosol or NP shedding (*P* \> 0.10). The association of vaccination and shedding was significant for influenza A (*P* = 0.03) but not for influenza B (*P* = 0.83) infections ([Table S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)).

Viral load in NP swabs was not a significant predictor of aerosol shedding (*P* = 0.16 for fine and *P* = 0.48 for coarse aerosols). Temperature measured at the time of sampling, asthma history, smoking, and influenza type were not significantly associated with the extent of measured shedding. While self-reported symptoms were not associated with aerosol shedding, they were significantly associated with shedding measured by the NP swab; only upper respiratory symptoms remained significant when adjusted for other symptoms and age. Increasing age was associated with a significant decrease in shedding in the NP swab; however, age was not associated with aerosol shedding.

Discussion {#s2}
==========

We recovered infectious influenza virus from 52 samples of fine aerosols collected from exhaled breath and spontaneous coughs produced by 142 cases of symptomatic influenza infection during 218 clinic visits. Finding infectious virus in 39% of fine-aerosol samples collected during 30 min of normal tidal breathing in a large community-based study of confirmed influenza infection clearly establishes that a significant fraction of influenza cases routinely shed infectious virus, not merely detectable RNA, into aerosol particles small enough to remain suspended in air and present a risk for airborne transmission. Because these data were collected without volunteers having to breathe through a mouthpiece or perform forced coughs, they allow us to provide estimates of average shedding rates, variability, and time course of and risk factors for shedding that can be used to provide well-grounded parameter estimates in future models of the risk of airborne influenza transmission from people with symptomatic illness.

The first published estimates of the numbers of influenza virus variants transmitted from donor to recipient host indicated that the bottleneck for transmission between humans is fairly wide and highly variable (mean 192 with 95% confidence 66--392) ([@r14], [@r15]). Our observation that cases shed considerable quantities of virus into aerosols, GM \>10^4^ RNA copies per 30 min, and up to 10^3^ infectious virus particles per 30 min, suggests that large numbers of variants could be transmitted via aerosols, especially via the short-range mode ([@r16]). However, longer-range aerosol transmission, as might be observed in less-crowded environments than in the initial report from Hong Kong, would be expected to usually result in lower exposures and transmission of fewer variants, consistent with the narrower bottleneck described in ferret models ([@r17], [@r18]).

Sobel Leonard et al. ([@r14]) suggested that the width of the bottleneck increased with severity of illness, as indicated by a borderline significant positive association between temperature and number of variants transmitted. We did not see a significant association between measured temperature and shedding by any route. In contrast, symptoms were not a significant predictor of bottleneck size, and in our data, symptoms were not significant predictors for shedding into aerosols. Symptoms were, however, significant predictors for nasal shedding as measured in NP swabs. Thus, if aerosols were the more important route of transmission, our observations would be consistent with the currently available bottleneck analysis.

We observed that influenza cases rarely sneezed, despite having just undergone two NP swab collections (a procedure that generally makes one feel an urge to sneeze). Sneezing was not observed in the absence of cough and was not associated with greater aerosol shedding than we observed with cough alone ([Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)). Thus, sneezing does not appear to make an important contribution to influenza virus shedding in aerosols. Sneezing might make a contribution to surface contamination. Because sneezes generate considerable amounts of large-droplet spray composed of many ballistic droplets not collected by our sampler, we cannot assess that possibility with our data.

Cough was prevalent and was a strong predictor of virus shedding into both coarse and fine aerosols. However, cough was not necessary for infectious aerosol generation in the ≤5-µm (fine) aerosol fraction; we detected culturable virus in fine aerosols during 48% of sampling sessions when no coughs were observed. This suggests that exhaled droplets, generated by mechanisms other than cough, are responsible for a portion of the viral load observed in the fine-aerosol fraction. Several researchers have recently shown that exhaled aerosol particles are frequently generated from normal healthy lungs by small airway closure and reopening ([@r19][@r20]--[@r21]). It has been hypothesized that during respiratory infections, airway closure and reopening frequency would be increased due to inflammation with a commensurate increase in aerosol generation and contagiousness ([@r22]).

Cough is thought to produce aerosols from large airways by shear forces that produce relatively coarse-aerosol droplets ([@r23]). Our finding that only 13% of cases not observed to have coughed during sample collection produced detectable viral RNA in their coarse aerosols is consistent with that hypothesis. The remaining aerosols may have resulted from speaking; each subject was required to recite the alphabet three times. One might expect that viral replication in the large airways combined with cough-generated coarse-aerosol droplets would produce the majority of viral aerosols. However, we observed a weak correlation of coarse-aerosol RNA copy number with cough frequency and a much stronger association of fine-aerosol copy number with cough frequency, even though cough would be expected to be the primary source of coarse aerosols. These observations suggest that cough is, at least in part, an epiphenomenon, more of a response to irritation associated with high viral loads in distal airways than a direct source of infectious aerosols.

A striking finding was the association of gender with shedding into fine aerosols. This relationship appears to have resulted from a threefold greater impact of coughing on shedding in males. We observed these gender and gender-by-cough interaction effects only for the fine-aerosol fraction. Absence of a gender effect in the coarse-aerosol fraction suggests that this is not an effect of cough on aerosol generation by shear forces in the upper airway. We did not measure lung volumes and therefore cannot control for a lung size effect. An equally plausible explanation may be that women tend to have more sensitive cough reflexes ([@r24]). Thus, women may have tended to cough in response to lower viral loads and coughed more frequently at a given viral load, which could have produced the observed steeper slope of viral load regressed on cough frequency in males compared with females. Consistent with this suggestion, we did observe a significantly greater cough frequency in females (*P* = 0.005) and a steeper slope of fine-aerosol viral RNA with cough in males ([Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)).

BMI was a borderline significant predictor of aerosol shedding in most models, was retained as an important predictor of both coarse and fine aerosols in adjusted models, and reached statistical significance for fine aerosols when adjusted for other factors; it was not a significant predictor of nasal shedding. This observation might be consistent with reports of increased inflammation in models of obesity and influenza and severity of influenza-like illness in obese persons ([@r25][@r26][@r27][@r28][@r29]--[@r30]). Alternatively, increasing BMI is associated with increased frequency of small airways closure, and the resulting increased aerosol generation during airway reopening as described above may explain the stronger association of BMI with fine than coarse aerosols and lack of association with NP swabs ([@r31]).

Our analysis found a clear separation of factors associated with shedding from the nose and those with shedding into aerosols, especially fine-particle aerosols. Upper airway symptoms, as would be expected, were strongly associated with shedding detected in NP swabs, and greatly reduced the size and significance of lower respiratory and systemic symptoms in the fully adjusted model. Age was negatively associated with nasal shedding but not a predictor of aerosol shedding. More surprisingly, no symptoms, including lower respiratory and systemic systems, were strongly associated with shedding into aerosols, in this population with relatively mild lower respiratory symptoms ([Fig. 1](#fig01){ref-type="fig"}). Furthermore, nasal shedding was not a significant predictor of aerosol shedding and none of the strong predictors of aerosol shedding were associated with nasal shedding. Thus, we can conclude that the head airways made a negligible contribution to viral aerosol generation and that viral aerosols represent infection in the lung. Moreover, upper and lower airway infection appear to behave as though infection is compartmentalized and independent. In this context, it is notable that Varble et al. ([@r18]) observed that intrahost viral variants differ in the nasopharynx and lung of ferrets.

We did not observe a significant decline over time of viral load detected in NP swabs. If day 1 after onset of symptoms (used as baseline for these analyses) in our cases was equivalent to a mixture of day 1 and day 2 after experimental influenza virus inoculation in the report by Hayden et al. ([@r32]), then our lack of finding a clear drop in nasal shedding over the next 2 d is reasonably consistent with the pattern reported for experimental infection. There is no available data for comparison of aerosol shedding from published experimental infections. That we saw a much clearer pattern of rapid decline over time in aerosol shedding again suggests a separation of infection into upper and lower airway compartments in humans.

The association of current and prior year vaccination with increased shedding of influenza A might lead one to speculate that certain types of prior immunity promote lung inflammation, airway closure, and aerosol generation. This first observation of the phenomenon needs confirmation. If confirmed, this observation, together with recent literature suggesting reduced protection with annual vaccination, would have implications for influenza vaccination recommendations and policies.

Materials and Methods {#s3}
=====================

Study Population and Sample Collection Procedures. {#s4}
--------------------------------------------------

We recruited volunteers with acute respiratory illness on the University of Maryland--College Park campus and surrounding community from December 2012 through March 2013. The University of Maryland Institutional Review Board approved the study, and we obtained a signed consent (or assent and parental verbal assent) from volunteers who reported fever with a cough or sore throat ([Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)).

During the initial visit, we administered a brief screening questionnaire, measured oral temperature, height, weight, and collected two NP swabs (Copan) for each volunteer screened. One swab was used to perform QuickVue A/B rapid tests for influenza (except when results of a rapid test performed by medical provider were available). The second NP swab was used for viral culture and PCR for those meeting enrollment criteria and for PCR in a random sample of 24 of those not enrolled.

Participants were asked about sex, age, antipyretic use, vaccination status, use of steroid medications, medical and smoking history, to rate current symptoms on a four-level scale (none = 0, mild = 1, moderate = 2, severe = 3), and to rate the worst symptoms during the illness thus far. We defined symptoms as upper respiratory (runny nose, stuffy nose, sneezing, sore throat, and earache), lower respiratory (chest tightness, shortness of breath, and cough), and systemic (malaise, headache, muscle/joint ache, fever/sweats/chills, and swollen lymph nodes).

Volunteers were enrolled in exhaled breath collection if they met the following criteria: (*i*) positive QuickVue rapid test, or oral temperature \>37.8 °C plus cough or sore throat, and (*ii*) presented within the first 3 d of symptom onset. Exhaled breath samples were collected using the Gesundheit-II (G-II) human source bioaerosol sampler, as previously described ([@r12], [@r33]). We collected exhaled breath for 30 min while the participant was seated with their face inside of the large open end of a cone-shaped inlet for the G-II. The inlet cone draws in 130 L of air per minute and allowed participants to breathe, talk, cough, and sneeze naturally throughout sample collection while maintaining \>90% collection efficiency for exhaled and coughed droplets ≤100 µm. Subjects were asked to breathe normally and to recite the alphabet once at 5, 15, and 25 min. We collected "coarse" (\>5 µm) aerosol droplets by impaction on a Teflon surface and "fine" droplets (≤5 µm and \>0.05 µm) by condensation growth and impaction on a steel surface constantly rinsed into a buffer containing (PBS with 0.1% BSA) liquid reservoir. Audible spontaneous coughs and sneezes during breath collection were counted by direct observation in real-time (*n* = 59) or by playback of digital recordings (*n* = 159).

Participants enrolled before the third day after symptom onset were asked to come in for up to two consecutive daily follow-up visits ([Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental)) with repeat questionnaire, NP swab, and exhaled breath collections. Final analyses included only visits for enrolled cases occurring on days 1--3 after symptom onset with complete data on cough and sneeze, symptoms, PCR results for swab and aerosol samples.

Laboratory Methods. {#s5}
-------------------

Detailed methods are described in the [*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental). Briefly, NP swabs were eluted in 1 mL of PBS with 0.1% BSA (PBS/0.1% BSA) or universal transport medium (Copan), and Teflon impactors were scrubbed with a nylon swab saturated with PBS/0.1% BSA. The swab was eluted in 1 mL PBS/0.1% BSA. Fine-aerosol samples were concentrated to 1 mL using centrifugal ultrafiltration.

RNA was extracted from NP swab, fine- and course-aerosol samples, and whole-virion standards using an automated Qiagen system and viral RNA was quantified by one-step real-time RT-PCR using Taqman primer probe sets designed by the US Centers for Disease Control and Prevention and made available through our cooperative agreement. Standard curves were calibrated for virus copy number using plasmids containing a cDNA copy of the qRT-PCR target amplicon. Experimentally determined limits of detection and quantification for each of the qRT-PCR reactions are shown in [Table S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental).

Virus culture on Madin--Darby canine kidney (MDCK) cells was used to detect infectious virus in NP swab and fine-aerosol samples. Coarse-aerosol samples were not cultured for infectious virus because impaction on a dry Teflon surface was expected to reduce infectivity of those samples. Infectious influenza virus was quantified using an immunofluorescence assay for influenza nucleoprotein, and positive cells were counted as FFU by fluorescence microscopy. Details of laboratory methods can be found in [*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1716561115/-/DCSupplemental).

Statistical Analysis. {#s6}
---------------------

We entered and cleaned data using locally hosted REDCap data-capture tools ([@r34]) and performed data management and analyses in R (v3.2.3 R Development Core Team, Vienna, Austria) and SAS (v9.4, Cary, NC), and produced graphics with Prism Software (PRISM software v7.0; GraphPad). We used the delta method to estimate confidence limits for sensitivity and specificity. We used Spearman correlation, generalized linear models (SAS Proc GENMOD), and Tobit regression ([@r35]) with nested random effects of sample within subject in (SAS Proc NLMIXED) to analyze infectious virus counts, RNA copy numbers, and compute GM virus concentrations. Tobit regression accounted for uncertainty and censoring of the observations by the limit of quantification. We included all independent variables with unadjusted *P* \< 0.10 in initial adjusted models and selected final models using the Akaike information criterion while retaining adjustment for age and sex. Regression model results are presented as the ratio of shedding at the 75th percentile to shedding at the 25th percentile of the distribution of the independent variable, so that clinical and epidemiological meaning of the relationship can be more easily interpreted.
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